Live Webinar: Rapid Monoclonal Antibody Development by Single B Cell Express Cloning – 10/05/21 | ASC

Free Webinar: Rapid Monoclonal Antibody Development by Single B Cell Express Cloning, Generating Rabbit Monoclonal Antibodies with Subnanomolar Affinity

Presenter: Xiaofeng Xia, PhD

Date: October 5, 2021

Time: 10 am PST

Duration: 40 min

Applied StemCell’s rapid monoclonal antibody development platform leverages single B cell express cloning technology to generate large quantities of high-affinity rabbit monoclonal antibodies. Our platform integrates unique rabbit strains/lines, optimized immunization protocols, and fast single B cell mRNA amplification for the production of novel monoclonal antibodies that can carry an endogenous reporter, be humanized, or be developed into nanobodies.

ASC invites anyone interested in antibody generation for preclinical research to join Dr. Xia on October 5, 2021, for a live webinar about our monoclonal antibody identification and amplification process. You will have the opportunity to learn about how our subnanomolar affinity monoclonal antibodies compare to others on the market and how you can benefit from the revolutionary platform to further your research. A Q&A session will be held at the end of the presentation. We look forward to seeing you there!

Webinar Topics 

• Technology overview, comparison & benefits
• Generation and characterization methods
• Case studies: COVID-19 antigen detection, VEGFA antibodies & more
• Q&A

About the Speaker:

Dr. Xiaofeng Xia received his PhD from Tsinghua University and completed his post-doc research at the University of Wisconsin-Madison. Before joining the biotech industry, he had two decades of academic research experience and was an assistant professor at Houston Methodist Research Institute and Weill Cornell Medical College of Cornell University.

Dr. Xia’s current research is on gene editing techniques and using gene edited animals for monoclonal antibody development. He established a platform named SBEAD for the rapid identification and production of high-affinity monoclonal antibodies. When used with the gene edited animals, SBEAD showed great potential in developing antibodies for diagnostics and therapeutics.

About Applied StemCell, Inc.

Applied StemCell, Inc. (ASC) is a fast-growing Gene & Cell Therapy CRO headquartered in California, USA. ASC was founded in 2008 with a goal to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. With more than 12 years of experience in genome editing and stem cell technologies, ASC is proud to develop innovative technology platforms offering services and products in the field of Stem Cells (iPSCs/ESCs, differentiated cells) and animal/cell models for disease modeling, antibody discovery & screening, bioproduction, AAV potency assays, cell therapy and regenerative medicine. Our Cell and Gene Therapy Bioservice platform also includes consultation for Pre-IND filing and CMC processes.

More information can be found at www.appliedstemcell.com.

Media Contact:
Maki Ogawa
Marketing Director, Applied StemCell, Inc.
408-773-8007
maki.ogawa@appliedstemcell.com